Literature DB >> 34775739

Assessment of pulmonary embolism severity and the risk of early death.

Piotr Pruszczyk, Marta Skowrońska, Michał Ciurzyński, Katarzyna Kurnicka, Mareike Lankei, Stavros Konstantinides.   

Abstract

Currently, venous thromboembolism, including deep vein thrombosis and acute pulmonary embolism (PE), is globally the third most frequent acute cardiovascular syndrome with rising incidence rates. The clinical presentation of PE is heterogenous: from incidental findings on imaging studies to sudden cardiac death. Hemodynamic instability identifies patients at high risk of early mortality. In hemodynamically stable patients, further stratification into intermediate- and low-risk categories is advised, preferably using a combined risk assessment strategy based on clinical parameters, laboratory findings, and imaging markers. Treatment should be tailored to the risk of early death, with more aggressive treatments reserved for patients at higher risk of complications. This review offers an update on the current strategies for assessing PE severity and the risk of early death and discusses developments in predicting mortality risk in patients with PE.

Entities:  

Mesh:

Year:  2021        PMID: 34775739     DOI: 10.20452/pamw.16134

Source DB:  PubMed          Journal:  Pol Arch Intern Med        ISSN: 0032-3772


  2 in total

1.  Left Ventricle Outflow Tract Velocity-Time Index and Right Ventricle to Left Ventricle Ratio as Predictors for in Hospital Outcome in Intermediate-Risk Pulmonary Embolism.

Authors:  Elena Emilia Babes; Manuela Stoicescu; Simona Gabriela Bungau; Diana Uivarosan; Delia Mirela Tit; Mirela Marioara Toma; Alexa Florina Bungau; Cristiana Bustea
Journal:  Diagnostics (Basel)       Date:  2022-05-13

Review 2.  Pathogenesis and Management of Brugada Syndrome: Recent Advances and Protocol for Umbrella Reviews of Meta-Analyses in Major Arrhythmic Events Risk Stratification.

Authors:  Hasina Masha Aziz; Michał P Zarzecki; Sebastian Garcia-Zamora; Min Seo Kim; Piotr Bijak; Gary Tse; Hong-Hee Won; Paweł T Matusik
Journal:  J Clin Med       Date:  2022-03-30       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.